VelocImmune technology
E579613
VelocImmune technology is Regeneron’s proprietary platform that uses genetically engineered mice to rapidly produce fully human monoclonal antibodies for therapeutic development.
Statements (39)
| Predicate | Object |
|---|---|
| instanceOf |
Regeneron proprietary technology
ⓘ
antibody discovery platform ⓘ biotechnology platform ⓘ |
| advantage |
high diversity of antibody repertoires
ⓘ
reduced risk of immunogenicity compared with chimeric antibodies ⓘ shortened timelines for antibody discovery ⓘ |
| appliedIn |
immunology drug development
ⓘ
infectious disease therapeutics ⓘ oncology drug development ⓘ rare disease therapeutics ⓘ |
| basedOn | genetically engineered mice ⓘ |
| commercialUse |
internal Regeneron drug pipeline
ⓘ
strategic collaborations with other pharmaceutical companies ⓘ |
| componentOf | Regeneron antibody discovery and development platform NERFINISHED ⓘ |
| developer | Regeneron Pharmaceuticals NERFINISHED ⓘ |
| enables |
in vivo affinity maturation
ⓘ
rapid antibody generation ⓘ |
| field |
biopharmaceuticals
ⓘ
immunology ⓘ therapeutic antibody engineering ⓘ |
| hasKeyFeature |
human immunoglobulin gene loci inserted into mouse genome
ⓘ
inactivation of mouse immunoglobulin genes ⓘ |
| intellectualPropertyStatus | patented technology ⓘ |
| notableProductAssociation |
REGN-COV2 antibody cocktail
NERFINISHED
ⓘ
dupilumab NERFINISHED ⓘ other Regeneron monoclonal antibody therapeutics ⓘ |
| owner | Regeneron Pharmaceuticals NERFINISHED ⓘ |
| produces | fully human monoclonal antibodies ⓘ |
| relatedTo |
Regeneron VelociSuite
NERFINISHED
ⓘ
VelociGene NERFINISHED ⓘ VelociMouse NERFINISHED ⓘ |
| supports |
clinical candidate selection
ⓘ
generation of antibody combinations ⓘ |
| technologyType |
in vivo antibody discovery system
ⓘ
transgenic animal platform ⓘ |
| usedFor |
generation of fully human monoclonal antibodies
ⓘ
preclinical drug development ⓘ therapeutic antibody discovery ⓘ |
| usesOrganism | transgenic mice ⓘ |
Referenced by (1)
Full triples — surface form annotated when it differs from this entity's canonical label.